The VICT3R consortium, led by Pompeu Fabra University (Spain) and Bayer Aktiengesellschaft (Germany), is a dynamic collaboration of 33 partner organizations. This diverse team includes 20 industry leaders, seven innovative small- and medium-sized enterprises, and six prestigious academic institutions. Together, they are dedicated to driving innovation and validating Virtual Control Groups (VCGs) to transform nonclinical safety evaluations, reduce animal testing, and promote ethical research practices. This united effort leverages cutting-edge technology and expertise to achieve groundbreaking advancements in drug and chemical safety assessments.
VICT3R Beneficiaries
Abbvie Inc
North Chicago, Illinois, United States
Amgen Research (Munich) GmbH
München, Germany
Astrazeneca Uk Limited
Cambridge, United Kingdom
Barcelona Supercomputing Center – Centro Nacional de Supercomputación
Barcelona, Spain
BASF SE
Ludwigshafen am Rhein, Germany
Bayer Aktiengesellschaft
Leverkusen, Germany
Boehringer Ingelheim International GmbH
Ingelheim, Germany
Bristol-Myers Squibb Company Corp
Princeton, NJ, United States
Deciphex
Dublin, Ireland
F. Hoffmann-La Roche AG
Basel, Switzerland
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Hanover, Germany
grit42
Copenhagen, Denmark
Incyte Biosciences Distribution B.V
Amsterdam, Netherlands
Instem
Stone Staffordshire, United Kingdom
Ipsen Innovation SAS
Les Ulis, France
Janssen Pharmaceutica Nv
Beerse, Belgium
Medbioinformatics Solutions SL
Barcelona, Spain
Merck Kommanditgesellschaft Auf Aktien
Darmstadt, Germany
Novartis Pharma AG
Basel, Switzerland
Novo Nordisk A/S
Bagsvaerd, Denmark
Organon SRL
București, Romania
Orion Corporation
Espoo, Finland
Pfizer Inc
New York City, United States
PHUSE CLG
Dublin, Ireland
Sanofi-Aventis Deutschland GmbH
Frankfurt / Main, Germany
Synapse Research Management Partners SL
Barcelona, Spain
Syncwork Aktiengesellschaft
Berlin, Germany
Takeda Pharmaceuticals International AG
Glattpark-Opfikon, Zurich, Switzerland
TU Dortmund University
Dortmund, Germany
UCB Biopharma
Brussels, Belgium
Universitat Pompeu Fabra
Barcelona, Spain
University of Konstanz
Konstanz, Germany
Vrije Universiteit Brussel
Brussel, Belgium
VICT3R beneficiaries
Universities, research organisations, public bodies, non-profit groups
Barcelona Supercomputing Center – Centro Nacional de Supercomputación
Barcelona, Spain
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Hanover, Germany
TU Dortmund University
Dortmund, Germany
Universitat Pompeu Fabra
Barcelona, Spain
University of Konstanz
Konstanz, Germany
Vrije Universiteit Brussel
Brussel, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
IHI industry partners
Abbvie Inc
North Chicago, Illinois, United States
Amgen Research (Munich) GmbH
München, Germany
Astrazeneca Uk Limited
Cambridge, United Kingdom
BASF SE
Ludwigshafen am Rhein, Germany
Bayer Aktiengesellschaft
Leverkusen, Germany
Boehringer Ingelheim International GmbH
Ingelheim, Germany
Bristol-Myers Squibb Company Corp
Princeton, NJ, United States
F. Hoffmann-La Roche AG
Basel, Switzerland
Incyte Biosciences Distribution B.V
Amsterdam, Netherlands
Ipsen Innovation SAS
Les Ulis, France
Janssen Pharmaceutica Nv
Beerse, Belgium
Merck Kommanditgesellschaft Auf Aktien
Darmstadt, Germany
Novartis Pharma AG
Basel, Switzerland
Novo Nordisk A/S
Bagsvaerd, Denmark
Orion Corporation
Espoo, Finland
Pfizer Inc
New York City, United States
Sanofi-Aventis Deutschland GmbH
Frankfurt / Main, Germany
Takeda Pharmaceuticals International AG
Glattpark-Opfikon, Zurich, Switzerland
UCB Biopharma
Brussels, Belgium
Barcelona Supercomputing Center - Centro Nacional de Supercomputación
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
TU Dortmund University
Universitat Pompeu Fabra
University of Konstanz
Vrije Universiteit Brussel
Deciphex
grit42
Medbioinformatics Solutions SL
Organon SRL, București, Romania
PHUSE CLG
Synapse Research Management Partners SL
Syncwork Aktiengesellschaft, Berlin, Germany
Abbvie Inc
Amgen Research (Munich) GmbH
Astrazeneca Uk Limited
BASF SE
Bayer Aktiengesellschaft
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company Corp
F. Hoffmann-La Roche AG, Basel, Switzerland
Incyte Biosciences Distribution B.V, Amsterdam, Netherlands
Ipsen Innovation SAS
Janssen Pharmaceutica Nv
Merck Kommanditgesellschaft Auf Aktien
Novartis Pharma AG
Novo Nordisk A/S
Orion Corporation, Espoo, Finland
Pfizer Inc
Sanofi-Aventis Deutschland GmbH
Takeda Pharmaceuticals International AG
UCB Biopharma
Instem, Stone Staffordshire
Advisors
VICT3R is supported by a Scientific and Regulatory Advisory Board (SRAB), which provides independent external advice to the project. The SRAB members bring expertise in key areas relevant to the project, helping to guide its scientific and regulatory strategy. The members are:
Susanne Brendler-Schwaab
BfArM (Federal Institute for Drugs and Medical Devices, Germany)
Ilona Kareinen
ECHA (European Chemicals Agency)
Roman Liska
ECVAM, JRC (European Centre for the Validation of Alternative Methods, European Commissions Joint Research Centre)
Peter van Meer
MEB (Medicines Evaluation Board, The Netherlands)
Patience Browne
OECD (Organisation for Economic Co-operation and Development)
Vera Rogiers
Toxicology Expert – independent
François Pognan
Toxicology Expert – independent
